Monthly Archives:

Low-Dose Prednisone Associated with Low Incidence of Corticosteroid-Associated AEs

New Orleans—Abiraterone acetate (AA) is the prodrug of abiraterone, which inhibits CYP17A1 and testosterone synthesis, prolonging survival of patients with metastatic castration-resistant prostate cancer (mCRPC). When AA is administered to mCRPC patients, a low dose of prednisone is also given. Long-term use of a moderate- or high-dose corticosteroid has an established adverse event (AE) profile. A recent analysis was conducted ... Read More »

Examining Prognostic Markers for Different Forms of Prostate Cancer

New Orleans—A recent study presented by Raisa Pompe and colleagues during a session at the AUA 2015 Annual Meeting indicated that multiparametric classifiers have a high potential to improve the predictive accuracy of distinguishing between indolent and aggressive forms of prostate cancer. Better prognostic markers are needed for prostate cancer, according to the researchers, and while single markers are not ... Read More »

OnabotulinumtoxinA Reduces Daily Urinary Incontinence Episodes

New Orleans—In patients with overactive bladder syndrome, treatment with onabotulinumtoxinA (onabotA) 100U resulted in consistent reductions in daily urinary incontinence episodes. That was among the findings of a study conducted recently by Victor Nitti, MD, and colleagues. Results of the multicenter, extension study were reported during a session at the AUA 2015 Annual Meeting. Patients were eligible to enter the ... Read More »

Cost Considerations for Enzalutamide for Castration-Resistant Prostate Cancer

New Orleans—Prostate cancer is associated with a high economic burden. A study examined the budget impact of adding enzalutamide for treatment of prostate cancer. The study was presented by Ken O’Day, PhD, MBA, and colleagues at the AUA 2015 Annual Meeting. Enzalutamide was approved by the FDA for the treatment of metastatic castration-resistance prostate cancer (mCRPC). The recommended dose is ... Read More »

Microdistribution of Radium-223 Dichloride in Models of PC Bone Metastasis Studied

New Orleans—Radium-223 dichloride (Ra-223) is a first-in-class alpha particle emitter producing a survival benefit for patients with late stage bone metastatic castration-resistant prostate cancer (bmCRPC). Dosed at 45 kBq per kg every 4 weeks for six total injections, the bone seeking radionuclide delivers four high-energy alpha particles across a path length of only several cell diameters. “Mechanism of action for ... Read More »

Educational Tools for Diagnosing and Treating Overactive Bladder

New Orleans—Despite the fact that overactive bladder (OAB) affects up to 20% of US adults, the condition remains underdiagnosed and undertreated. OAB can negatively impact social, psychological, occupational, domestic, physical, and sexual functioning. A recent study sought to evaluate the effectiveness of an online personalized learning curriculum in order to improve OAB diagnosis and care among primary care physicians (PCPs). ... Read More »

Study Examines Shared Decision-Making among Patients with Prostate Cancer

New Orleans—For men with prostate cancer, shared decision-making among the patient and the healthcare provider is often recommended, though poorly documented, as no study to date has recorded shared decision-making behaviors during a urologic consultation. Shared decision-making has been endorsed as a key component to improving the quality of decision-making in urology. A pilot feasibility study presented by Alan L. ... Read More »

Practice Patterns for Prostate Cancer among Urologists

New Orleans—Opinions vary on whether prostate cancer treatment patterns differ for urologists working in practices with or without the ownership of radiation oncology services. A recent study presented during a session at the AUA 2015 Annual Meeting found that the number of prostate biopsies performed per patient visit were similar among urologists both with and without ownership of a radiation ... Read More »

Risk Stratification Methods for Active Surveillance of Prostate Cancer

New Orleans—Many men with localized prostate cancer utilize active surveillance during treatment. A recent study presented by Jack Cuzick, PhD, during a session at the AUA 2015 Annual Meeting noted that better risk stratification is needed to appropriately select men for active surveillance. The cell cycle progression (CCP) score is based on measuring the expression levels of CCP genes and ... Read More »

PHI to Predict Upgrading of Prostate Cancer Patients on 5ARI

New Orleans—Low-risk prostate cancer patients eligible for active surveillance may not be accurately identified via a single transrectal biopsy (TRUS); resampling is often recommended for more accurate classification. Results of recent studies have suggested that the Beckman Coulter Prostate Health Index (PHI) is a significant predictor of high-grade prostate cancer, defined as Gleason score of greater than seven. However, according ... Read More »